தன்னாட்சி சமூக ஆஃப் மாட்ரிட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Study elucidates the role of two isoforms of KRAS oncogenes KRAS was one of the first oncogenes to be identified, a few decades ago. It is among the most common drivers of cancer and its mutations can be detected in around 25 per cent of human tumors. The development of KRAS inhibitors is, thus, an extremely active line of research. Effective results have been elusive so far, though - no KRAS inhibitor had been available until a month ago, when the FDA granted approval to Sotorasib. KRAS encodes two gene products, KRAS4A and KRAS4B, whose levels can vary across organs and embryonic stages. When KRAS mutates, both variants, or isoforms, are activated. Though, some studies have focussed on approaches to target only KRAS4B, since it usually found to be expressed at higher levels in tumors.

Mariano barbacidEduardo caleirasMarina salmMatthias drostenSagrario ortegaGuillem paniaguaEmily hendersonAutonomous community of madridInstitute of health carlosExperimental oncology groupSpanish ministry of scienceEuropean research councilResearch fundExperimental oncology programmeOncology groupMouse genomic editing core unit